Eli Lilly and Company Aktie News

Omvoh now offers patients a simplified maintenance experience with one monthly injection, replacing the previous two-injection regimen  Omvoh single-injection dosing will be available for U.S. patients in early 2026 This is the third FDA approval for Omvoh this year, following approvals for Crohn's disease and a citrate-free formulation INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- Eli Lilly and...

INDIANAPOLIS , Oct. 27, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2025 of $1.50 per share on outstanding common stock. The dividend is payable on December 10, 2025, to shareholders of record at the close of business on November 14, 2025.

Argenx SE is a biotechnology company best known for developing Vyvgart, the leading FcRn inhibitor for the treatment of autoimmune conditions. RadNet, Inc. is the largest operator of outpatient diagnostic imaging services and related solutions in the U.S. Intuitive Surgical, Inc. manufactures the da Vinci Surgical System, a robotic surgical system used for minimally invasive surgical procedures.

BDF-GESTION sold 4,149 shares of Eli Lilly and Company; Transaction value was $3.1 million Transaction represents 0.37% of BDF-GESTION's 13F reportable assets under management Post-trade stake: 19,949 shares valued at $15.22 million as of September 30, 2025 Position now represents 1.8% of fund AUM, which places it outside the fund's top five holdings

Eli Lilly is one of the largest drug companies in the world. The pharmaceutical giant's stock price is 15% below its 2024 high-water mark.

Eli Lilly (LLY) shares have surged by 16% over the last month and are currently priced at $825. U.S. pharmaceutical stocks have done well of late, as large drugmakers such as Pfizer and AstraZeneca signed drug pricing agreements with the Trump Administration to cut prescription drug prices and boost domestic manufacturing investments.

Wall Street expects good news when Lilly announces its Q3 results on Oct. 30. Lilly's stock might not perform as you think it will, even if it beats analysts' estimates.

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time — reflecting the spectrum of its burden on patients By Week 12, patients experienced a 55% reduction in daily episodes of bowel urgency from baseline, with severity reduced by more than half by Week 28 At Week 28, nearly one-third of p...